iShares Biotechnology ETF (NASDAQ:IBB) Shares Acquired by HBK Sorce Advisory LLC

HBK Sorce Advisory LLC lifted its position in iShares Biotechnology ETF (NASDAQ:IBB) by 5.3% in the fourth quarter, Holdings Channel reports. The firm owned 2,196 shares of the financial services provider’s stock after acquiring an additional 110 shares during the period. HBK Sorce Advisory LLC’s holdings in iShares Biotechnology ETF were worth $290,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in IBB. BNP Paribas Financial Markets boosted its position in shares of iShares Biotechnology ETF by 29.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,380,229 shares of the financial services provider’s stock valued at $346,561,000 after purchasing an additional 538,899 shares during the period. Raymond James Financial Inc. acquired a new stake in iShares Biotechnology ETF during the 4th quarter worth approximately $55,010,000. Healthcare of Ontario Pension Plan Trust Fund lifted its position in iShares Biotechnology ETF by 32.9% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock worth $96,533,000 after acquiring an additional 164,000 shares during the period. Aprio Wealth Management LLC purchased a new position in shares of iShares Biotechnology ETF in the 4th quarter valued at approximately $18,476,000. Finally, Generali Investments CEE investicni spolecnost a.s. purchased a new position in shares of iShares Biotechnology ETF in the 4th quarter valued at approximately $11,370,000. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Trading Up 0.8 %

Shares of IBB stock opened at $134.19 on Friday. The business’s 50 day moving average is $136.25 and its two-hundred day moving average is $139.81. iShares Biotechnology ETF has a twelve month low of $123.60 and a twelve month high of $150.57. The company has a market capitalization of $6.34 billion, a P/E ratio of 24.52 and a beta of 0.84.

iShares Biotechnology ETF Cuts Dividend

The business also recently announced a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were paid a $0.0624 dividend. The ex-dividend date of this dividend was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.